

Michiel J Thomeer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/299928/publications.pdf>

Version: 2024-02-01

69
papers

6,269
citations

201575

27
h-index

114418

63
g-index

77
all docs

77
docs citations

77
times ranked

6922
citing authors

#	ARTICLE	IF	CITATIONS
1	Passage of Inhaled Particles Into the Blood Circulation in Humans. <i>Circulation</i> , 2002, 105, 411-414.	1.6	1,380
2	High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2005, 353, 2229-2242.	13.9	880
3	Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2009, 374, 222-228.	6.3	464
4	Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1382-1389.	2.5	390
5	Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1231-1237.	2.5	369
6	Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 459-466.	2.5	367
7	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 948-955.	2.5	338
8	Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. <i>European Respiratory Journal</i> , 2008, 31, 1189-1196.	3.1	271
9	Methotrexate vs Azathioprine in Second-line Therapy of Sarcoidosis. <i>Chest</i> , 2013, 144, 805-812.	0.4	210
10	Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2008, 31, 585-591.	3.1	138
11	Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. <i>Thorax</i> , 2005, 60, 32-38.	2.7	124
12	REGISTRATION OF INTERSTITIAL LUNG DISEASES BY 20 CENTRES OF RESPIRATORY MEDICINE IN FLANDERS. <i>Acta Clinica Belgica</i> , 2001, 56, 163-172.	0.5	118
13	The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. <i>Frontiers in Oncology</i> , 2019, 9, 1215.	1.3	97
14	Glutamine Addiction and Therapeutic Strategies in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 252.	1.8	82
15	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. <i>Annals of Oncology</i> , 2013, 24, 986-992.	0.6	76
16	Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. <i>Thorax</i> , 2012, 67, 938-940.	2.7	71
17	Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. <i>Respiratory Research</i> , 2009, 10, 101.	1.4	70
18	Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. <i>Experimental Lung Research</i> , 2010, 36, 602-614.	0.5	57

#	ARTICLE	IF	CITATIONS
19	Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. <i>Respiratory Medicine</i> , 2004, 98, 567-573.	1.3	55
20	Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 516-523.	0.5	54
21	Medical thoracoscopic lung biopsy in interstitial lung disease: a prospective study of biopsy quality. <i>European Respiratory Journal</i> , 1999, 14, 585.	3.1	51
22	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1458-1467.	0.5	50
23	Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?. <i>European Respiratory Journal</i> , 2020, 56, 2001201.	3.1	50
24	Are Randomized Controlled Trials the (G)old Standard? From Clinical Intelligence to Prescriptive Analytics. <i>Journal of Medical Internet Research</i> , 2016, 18, e185.	2.1	39
25	Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. <i>Lung Cancer</i> , 2018, 115, 49-55.	0.9	38
26	An Algorithm to Tackle Acute Exacerbations in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1397-1397.	2.5	33
27	Clinical use of biomarkers of survival in pulmonary fibrosis. <i>Respiratory Research</i> , 2010, 11, 89.	1.4	28
28	Phenotyping human blood plasma by 1H-NMR: a robust protocol based on metabolite spiking and its evaluation in breast cancer. <i>Metabolomics</i> , 2015, 11, 225-236.	1.4	28
29	Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS. <i>Neurology</i> , 2003, 61, 1150-1151.	1.5	27
30	Influence of preanalytical sampling conditions on the 1H NMR metabolic profile of human blood plasma and introduction of the Standard PREanalytical Code used in biobanking. <i>Metabolomics</i> , 2015, 11, 1197-1207.	1.4	27
31	Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). <i>Journal of Thoracic Oncology</i> , 2016, 11, 85-93.	0.5	26
32	Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?. <i>Annals of Oncology</i> , 2016, 27, 178-184.	0.6	24
33	Hypogonadism in male outpatients with sarcoidosis. <i>Respiratory Medicine</i> , 2007, 101, 2502-2510.	1.3	23
34	Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 7-12.	0.7	19
35	A RANDOMIZED PLACEBO CONTROLLED TRIAL ASSESSING THE EFFICACY AND SAFETY OF ETANERCEPT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). <i>Chest</i> , 2005, 128, 496S.	0.4	15
36	Plausibility and redundancy analysis to select FDG-PET textural features in non-small cell lung cancer. <i>Medical Physics</i> , 2021, 48, 1226-1238.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET. <i>EJNMMI Research</i> , 2021, 11, 4.	1.1	15
38	Systemic lupus erythematosus, eosinophilia and LÃ¶ffler's endocarditis. An unusual association. <i>European Respiratory Journal</i> , 1999, 13, 930.	3.1	14
39	Metabolic phenotyping of human plasma by ¹ H-NMR at high and medium magnetic field strengths: a case study for lung cancer. <i>Magnetic Resonance in Chemistry</i> , 2017, 55, 706-713.	1.1	13
40	The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer. <i>BMC Cancer</i> , 2018, 18, 868.	1.1	13
41	Impact of acute exacerbations of COPD on patients' health status beyond pulmonary function: A scoping review. <i>Pulmonology</i> , 2023, 29, 518-534.	1.0	11
42	Remote patient monitoring in COVID-19: a critical appraisal. <i>European Respiratory Journal</i> , 2022, 59, 2102697.	3.1	9
43	A New Missense Mutation in the CASR Gene in Familial Interstitial Lung Disease with Hypocalciuric Hypercalcemia and Defective Granulocyte Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 558-559.	2.5	8
44	2015, big data in healthcare: for whom the bell tolls?. <i>Critical Care</i> , 2015, 19, 171.	2.5	8
45	A breathless accountant who blew up balloons. <i>Lancet, The</i> , 1999, 354, 124.	6.3	7
46	Pertechnegas lung clearance in different forms of interstitial lung disease. <i>European Respiratory Journal</i> , 2002, 19, 31-36.	3.1	7
47	Correlations between the metabolic profile and 18F-FDG-Positron Emission Tomography-Computed Tomography parameters reveal the complexity of the metabolic reprogramming within lung cancer patients. <i>Scientific Reports</i> , 2019, 9, 16212.	1.6	7
48	Sarcoidosis around the Globe. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 393-403.	0.8	6
49	Detection of Lung Cancer via Blood Plasma and 1H-NMR Metabolomics: Validation by a Semi-Targeted and Quantitative Approach Using a Protein-Binding Competitor. <i>Metabolites</i> , 2021, 11, 537.	1.3	6
50	Disseminated <i>Mycobacterium tilburgii</i> infection in a non-HIV-infected patient. <i>Clinical Microbiology Newsletter</i> , 2007, 29, 62-64.	0.4	5
51	Newer modes of treating interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2011, 17, 332-336.	1.2	5
52	Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT.. <i>Journal of Clinical Oncology</i> , 2011, 29, 7002-7002.	0.8	5
53	Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review. <i>Metabolites</i> , 2022, 12, 545.	1.3	4
54	MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7013-7013.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5602.	1.8	3
56	External validity of randomised controlled trials in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2006, 27, 1072.1-1072.	3.1	2
57	CATEGORICAL DECLINES IN PERCENT PREDICTED FORCED VITAL CAPACITY (PP-FVC) ARE ASSOCIATED WITH A GRADED RISK OF DEATH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). <i>Chest</i> , 2008, 134, 20S.	0.4	2
58	6-Minute Walk Test Distance (6MWD) Is A Reliable, Valid, And Responsive Outcome Measure That Predicts Mortality In Patients With IPF. , 2010, , .		2
59	Metabolomics a Novel Biomarker in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, e46.	0.5	2
60	New Idiopathic Pulmonary Fibrosis Guidelines: Some Unresolved Questions. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 588-588.	2.5	1
61	Validation of 1H-Nmr-Based Metabolomics As a Tool to Detect Lung Cancer in Human Blood Plasma. <i>Annals of Oncology</i> , 2014, 25, iv406.	0.6	1
62	Classification and new developments in the pathogenesis of vasculitis. , 2005, , 50-68.		1
63	Diffuse interstiële longaandoeningen: actuele inzichten in diagnostiek en ziekteopvolging. <i>Tijdschrift Voor Geneeskunde</i> , 2001, 57, 953-962.	0.0	1
64	Treatment strategies for sarcoidosis. <i>Acta Clinica Belgica</i> , 2012, 67, 83-7.	0.5	1
65	New Idiopathic Pulmonary Fibrosis Guidelines: Some Unresolved Questions. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 588-589.	2.5	0
66	Diagnosis of Lung Cancer: What Metabolomics Can Contribute. , 2018, , .		0
67	Fever and an abnormal chest X-ray during the COVID-19 pandemic. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101167.	0.2	0
68	Clinical manifestation, approach to diagnosis and treatment of pulmonary vasculitis. , 2005, , 69-90.		0
69	Sarcoïdose: een adembenemende aandoening. <i>Tijdschrift Voor Geneeskunde</i> , 2007, 63, 987-994.	0.0	0